Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Neoplasms
  • Taxoids

abstract

  • The MTD and recommended dose for phase II evaluations of BMS-184476 is 60 mg/m2 as a 1-hour IV infusion every 3 weeks. The results of this study suggest that BMS-184476 may have several advantages compared with paclitaxel in terms of toxicity, pharmacokinetics, pharmaceutics, and administration and warrants further clinical development.

publication date

  • May 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2001.19.9.2493

PubMed ID

  • 11331328

Additional Document Info

start page

  • 2493

end page

  • 503

volume

  • 19

number

  • 9